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Introduction 
In acute myocardial infarction (AMI), ischemia initiate the necrosis and apoptosis of 
millions or even more than a billion cardiomyocytes.1 After weeks of inflammation and 
reparative processes, these cells are largely replaced by scar tissue. Substantial loss of 
functional myocardium leads to acute heart failure, but even moderate infarcts may increase 
the strain/stress on remaining cardiomyocytes, and thereby induce a maladaptive 
compensatory response leading to congestive heart failure (CHF). This change in 
myocardial structure and left ventricular (LV) geometry, often referred to as remodeling, 
may act beneficially in the shorter term to increase stroke volume, but is in the long run 
associated with a poor outcome.2 Ischemic heart disease and congestive heart failure are 
important causes of morbidity and death in industrialized countries.3  
The pathophysiology in CHF is incompletely understood. Through history, different 
pathophysiological models have each made important intellectual and therapeutic 
contributions. The cardiorenal model implemented the use of diuretics, vasodilatators and 
inotropic drugs, alleviating oedemas and releaving symptoms, but with dubious prognostic 
effects. Later, the neurohormonal model introduced angiotensin converting enzyme (ACE)- 
inhibitors, betablockers, angiotensin receptor blockers (ARBs) and aldosterone-antagonists. 
In large, randomized-controlled trials, their effects on morbidity and mortality were well 
documented through the 1980s and -90s, and these drugs are still cornerstones in treatment 
in CHF and after AMI.4, 5 At the end of the 90s, a cardioinflammatory model was 
introduced, clarifying important steps in the pathophysiology of CHF. New potential targets 
for therapeutic interventions were revealed, but in clinical trials, most of these interventions 
have failed to prove clinically effective (i.e. TNF-	

6, BNP (Nesiritide®)7, and 
immunoglobulins8). In end–stage heart failure, heart transplantations or ventricular assist 
devices may save lives in selected groups of patients. However, the availability of donor 
organ is limited, and patients are exposed to the risks for rejection and complications of 
high-intensity immunosuppression. The ventricular assist devices have improved with the 
introduction of non-pulsatile rotations pumps, but this therapy is still expensive with high 
risk for infections and thromboembolic events. Thus, mortality in post-infarction CHF 
remains high, and new therapeutic options are needed. 
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The heart as a self-renewing organ 
The heart has for centuries been regarded a terminally differentiated organ without 
regenerative capacity after birth. Mitotic figures in cardiomyocytes were rarely identified in 
the light microscope, and in response to injury, contractile cells were replaced by scar tissue. 
Even in the process of cardiac hypertrophy, cells seemed to increase in volume, and not in 
number.9, 10 In the last decade, this paradigm has been challenged. A cardiac stem cell has 
been identified, and proliferative activity has been documented.11 Bergmann et al. have, 
with analyses of the C14 isotope, provided evidence that the heart is self-renewing, but at a 
slow rate.12 Kajstura et al. suggest a more rapid turnover of cardiomyocytes, based on 
histological staining for protein markers of cell division (Ki67 and phospho-H3) and 
apoptotic cell death (p16INK4a).13 However, clinical experience tells us that the hearts 
intrinsic regenerative capacity is insufficient when challenged by substantial myocardial 
damage like AMI, myocarditis, or cardiotoxic drug therapy. 
 
Cell therapy  
Bone marrow transplantations have been performed successfully since 1959 for 
hematological or malignant disorders, showing that allogeneic cells may reconstitute bone 
marrow function in the recipient. The stem cells themselves (colony forming units) were not 
identified until 1963, but their role in the hematopoietic system has been well described.14, 15 
Stem cells are defined by 3 important characteristics;  
 self-renewal  
 potency- the ability to differentiate to specialized cell types and  
 the ability to reconstitute a tissue.  
 
Thus, stem cells may undergo symmetric division to provide two stem cells or two 
differentiated daughter cells, or asymmetric cell division to provide one stem cell and 
one differentiated daughter cell. Stem cells have been classified according to their 
potential for differentiation: 
 Totipotent stem cells= the fertilized oocyte and descendants until the 8-cell stage of 
embryonic development. 
 Pluripotent stem cells= stem cells able to differentiate to all three germ layers 
(endo-, ecto-, and mesoderm), i.e. embryonic stem cells (ESCs). 
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 Multipotent stem cells= stem cells able to differentiate to > 1 lineage of daughter 
cells. Mesenchymal stem cells and hematopoietic stem cells are examples of 
multipotent stem cells. 
 Unipotent stem cells= cells capable of differentiation to one cell type. Also called 
progenitor cells. Endothelial progenitor cells (EPCs), cardiac stem cells (CSCs) and 
skeletal myoblasts are all examples of unipotent stem cells.       
 
Stem cells have been identified in most organs, including the heart, suggesting a potential 
for regeneration of lost cells. Stimulation of endogenous stem cells- either circulating or 
resident in situ, direct transplantation of stem cells, and tissue engineering are the most 
important approaches in this field of therapy, often referred to as regenerative medicine. 
Repopulating the heart with functional cardiomyocytes could, in theory, be a causal and 
definite therapy after larger a large AMI or in CHF. Different approaches have been 
explored experimentally and clinically, as methodology and experience have progressed. In 
the early 1990s, skeletal myoblasts, also called satellite cells, were the first cells used.16 
These cells were striated and contractile like cardiomyocytes, but easier to harvest and 
culture. In experimental models, implanted cells were readily identifiable in the host 
myocardium, remodeling was abrogated, and LV function improved.17 Unfortunately, 
further studies revealed that the transplanted myoblasts did not couple electrically with the 
host myocardium.18 In clinical trials, increased risk of arrhythmias was observed, and 
implantable cardioverter-defibrillators (ICDs) had to be implanted in all recipients. In the 
first clinical phase II trial, MAGIC19, the increased burden of ventricular arrhythmias was 
confirmed, and no significant benefit was found on the primary endpoint LV ejection 
fraction (LVEF). This discouraging result practically terminated further clinical research on 
cardiac myoblast therapy. 
In 2001, Orlic et al. reported substantial engraftment, myocardial differentiation and 
improvement in LV function when bone marrow cells (BMCs) were injected into the heart 
after myocardial infarction in mice.20 Although the results evoked scientific controversy1, 21, 
22, the use of BMCs was rapidly translated directly from small animals to human trials. 
Already in 2002, Strauer et al. presented a cohort-study on patients treated with 
intracoronary infusion of bone marrow cells after AMI.23 The mononuclear BMCs 
(mBMCs) had been isolated by gradient centrifugation in a polysaccharide suspension 
(Ficoll) and were subsequently infused in the infarct related coronary artery (IRA) through a 
percutaneous coronary intervention (PCI)- catheter (figure 1). The PCI- balloon was inflated 
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at the site of former coronary occlusion to stop flow for 2-4 minutes while 2-3 ml of cell-
suspension was infused, to allow time for cells to adhere to and migrate through the vessel 
wall. Then, the balloon was deflated to allow blood-flow for a few minutes and the 
procedure was repeated 6 to 7 times to infuse all cells. 
 
Figure 1. Intracoronary cell- injection by stop-flow technique. 
 
B Strauer et al. Circulation 2002:106;1913-1918. Used with permission from the publisher. 
 
In Strauer’s hands, the method appeared safe and patients treated with mBMC injections 
had decreased infarct size and improved regional LV function after 3 months when 
compared to the control group. Patients who refused participation in the cell therapy group 
served as controls, thus, this was not a randomized study. However, the results were 
encouraging and the “stop-flow” technique was adopted by subsequent clinical trials. 
Although the mechanisms of action, dose-response relationship, best route of 
administration, and optimal timing of cell therapy were still unclear, several small or 
medium sized randomized studies were initiated to further explore the potential of this new 
treatment. The Norwegian ASTAMI study was initiated in 2003, and the primary results 
were published in 2006.24 The trial design and results after 6- and 12 months have been 
presented and discussed in previous publications and the dissertations by Ketil Lunde and 
Svein Solheim.24-28 In ASTAMI, mBMC therapy did not improve LVEF after 6 months 
compared to the control group. In contrast, the contemporary REPAIR- AMI study showed 
significant improvement in LVEF 4 months after cell therapy.29 These apparently 
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conflicting results evoked a controversy on cell preparation procedures.30-33 However, both 
studies included a limited number of patients, without power to determine effects on clinical 
outcome. The results of most small and medium sized trials on mBMC therapy have been 
summarized in several meta-analyses34-36 and a schematic overview of studies with 
patients and/or long term follow-up data are presented in table 1. Based on data in these 
meta-analyses, mBMC-therapy after AMI is considered safe. Although PCI procedures are 
potentially harmful, and possible side effects of bone marrow aspirations and PCI 
procedures have been reported37-39, adverse events are not overrepresented in the cell treated 
patients. The pooled data in the Cochrane-based meta-analysis34 suggest a modest beneficial 
treatment -effect on LVEF of 3 % (percentage-points) after 4-6 months of observation. 
However, experimental data show that the engraftment of injected cells is poor40-42, and that 
differentiation of bone marrow cells to cardiomyocytes after injection hardly occurs.21, 22 
Thus, after these early trials a move “back to the bench” was suggested- to search for more 
efficient cells and to clarify mechanisms of action, optimal cell dosing, timing and route of 
cell administration.43 Clinical data from long term follow-up of patients treated with mBMC 
therapy were also requested34, 43 The treatment modality was only recently introduced, 
patients in most studies had been followed for only 4-6 months, and beneficial effects were 
discrepant. Thus, it was imperative to obtain long term follow- data on safety and efficacy in 
patients from the ASTAMI trial, one of the largest trials in this field. Based on these 
considerations, we performed a 3 year follow-up of patients in the ASTAMI- trial, and 
initiated a preclinical project to investigate effects of other cells. In 2006, Norwegian 
legislation did not permit research on ESCs. Results in clinical studies with myoblasts and 
mBMCs were rather disappointing. In the population in need of cardiac cell therapy, 
autologous CPCs were considered very rare and difficult to culture (personal 
communication, prof. Philippe Menasche, Paris, France). Mesenchymal stem cells (MSCs) 
constitute a small fraction (0.001-0.01 %) of BMCs and were described by Pittenger et al in 
1999.44 They are easily cultured, and characterized in culture by adherence to plastic 
surfaces. By definition, these cells have multilineage potential, forming fat, cartilage or 
bone when cultured in conditioned media. In specific conditions, the cells have also been 
stimulated to express markers of endothelial-, smooth muscle- and even cardiomyocyte 
phenotypes in culture.45, 46 Like the skeletal myoblasts, MSCs are relatively large and 
adhesive cells that may cause vascular plugging47, and large numbers of cells are therefore 
rarely infused in systemic arteries. Cells have been administered either by catheter-based 
transendocardial injections, as i.v. infusions, or as direct intramyocardial injections during 
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surgery.48-50 The majority of MSCs administered i.v. will be trapped in the pulmonary 
circulation.51 Early experimental studies reported improved LV function, reduced infarct 
size and improved vascular density after MSC injections.45, 50, 52-54 The mechanisms of 
action were, however, not clarified. Cells with an MSC phenotype had also been isolated 
from other, more easily available tissues like fat (ADSCs) and skeletal muscle.55 The 
potential for myocardial regeneration by use of these new cell lines was unknown, and head-
to-head comparisons of the effects of MSCs from different tissues had not been published. 
Availability, expandability, the theoretical potential for differentiation, and existing 
experimental results suggested MSCs as an attractive potential cell type for cardiac 
regeneration. We therefore sought to establish an animal model to test these cells by 
intramyocardial injection after AMI. The ASTAMI long term follow- up and the 
experimental studies on adipose tissue- and skeletal muscle derived stem cells were initiated 
in 2007 as a PhD- project.  
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Table 1. Randomized controlled studies on cardiac BMC therapy in AMI. # 
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Aims of the thesis 
The aims of the present work were: 
 
1. To perform a follow-up of patients in the ASTAMI study 3 years after randomization 
for evaluation of long term efficacy and safety, including recording of clinical 
events, physical examination, the SF-36 quality-of-life survey, blood biochemistry 
analyses, echocardiography, exercise testing, and cardiac MRI (paper I). 
 
2. To perform a comprehensive analysis of all echocardiographic recordings from 
baseline to 3 years follow-up in patients from the ASTAMI study, including systolic, 
diastolic and regional function (paper II). 
 
3. To establish an experimental model for cell therapy in acute myocardial infarction. 
 
4. To evaluate the effects of mesenchymal stem cells (MSCs) harvested from skeletal 
muscle and adipose tissue in a translational model of intramyocardial cell injection 
in AMI (paper III). 
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Subjects and methods (clinical study) 
Patients 
The ASTAMI study was an open-labeled, randomized controlled clinical trial. All patients 
admitted to Rikshospitalet University Hospital (RH) and Ullevål University Hospital (UUS) 
in the period September 2003 to May 2005 for acute PCI due to ST-segment elevation 
myocardial infarction (STEMI) were screened for inclusion (n=1608). 
 
Inclusion criteria (all criteria had to be fulfilled): 
 Age between 40 and 75 years 
 Acute anterior wall myocardial infarction with a history >3 and <12 hours 
 ST-elevation infarction (WHO ECG criteria) 
 Angiographic criteria: Occlusion (TIMI flow 0-1) of the left anterior descending 
(LAD) coronary artery proximal to the second diagonal branch. 
 Successful primary or rescue PCI (TIMI flow 2 or better) 
 Echocardiographic criteria: Evidence for anterior wall infarction as judged by hypo- 
or akinesia in more than 2 adjacent anterior wall segments. 
 Enzymatic criteria: CK-MB mass >3 times upper normal value 
 
Exclusion criteria: 
 Previous myocardial infarction with established significant Q-waves on ECG. 
 Cardiogenic shock. 
 hemodynamic instability necessitating intraaortic balloon pump treatment. 
 Permanent pacemaker or other contraindications to magnetic resonance imaging 
(MRI). 
 Stroke with significant sequela. 
 Short life expectancy due to extra cardiac reason, i.e. chronic obstructive lung 
disease, disseminated malignant disease, or other reason. 
 Uncontrolled endocrinological disturbance. 
 Anamnestic indications for significant mental disorder, including dementia. 
 Established HIV or hepatitis B infection. 
 Any condition which interferes with the patients’ possibility to comply with the 
protocol. 
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After written, informed consent, study participants were randomized 1:1 to intracoronary 
injection of autologous mBMCs 4 to 8 days after the acute event (n=50), or to a control 
group where neither bone marrow aspiration nor sham coronary procedure were performed 
(n=50). Three patients allocated to the mBMC group did not receive intracoronary cell 
injections (due to stent-thrombosis preceding the cell infusion in two patients, cell viability 
<90 % in one patient). 
The primary endpoint in ASTAMI was the change in LVEF from baseline to 6 months 
measured by single photon emission computed tomography (SPECT). MRI and 
echocardiography were used for serial assessment of LV function. Secondary endpoints 
were changes in exercise capacity and quality-of-life (QoL). Clinical events, infarct size, 
and multiple inflammatory and other biochemical markers were also evaluated. An 
echocardiogram and evaluation of clinical status after 12 months finished the initial 
protocol. The main results from the first 12 months of follow-up have been presented 
previously.24-28 The follow-up after 3 years was not part of the original study protocol. Thus, 
a new study protocol was written and approved by the regional committee for ethics in 
medical research. Patients provided a new written, informed consent. At 3 years, one patent 
refused further clinical follow-up and 2 patients were dead. Thus, 97 patients were eligible 
for the extended study. Medical history, clinical examination, SF-36 QoL-questionnaire, 
exercise testing, transthoracic echocardiography and cardiac MRI were performed. To 
minimize patient hazard, SPECT and routine coronary angiography were not performed at 3 
years.  
 
Cell processing and injection 
From patients in the mBMC group, 49±9 mL (mean±SD) bone marrow in 10.000 IU 
heparin was harvested from the iliac crest 4 to 7 days after AMI. The aspirate was diluted in 
75 ml 0.9% saline, and the mononuclear cell fraction was isolated by Isopaque-Ficoll 
(Lymphoprep©, Axis-Shield, Oslo Norway) gradient centrifugation. The mBMCs were 
washed 3 times, resuspended in 11 mL 0.9 % saline with 20 % heparin-plasma and stored 
over night. Median cell viability, as assessed by an acridin orange/ethidium bromide 
exclusion assay, was 95 %. The median number of injected viable cells was 68 x 106 
(interquartile range 54x106 to 130x106). The cell products were processed in an accredited 
cell production facility under Good Manufacturing Practice (GMP) conditions. 
Approximately 10 mL of cell suspension was injected by PCI on LAD with the stop flow 
technique 5 to 8 days after the AMI. One third of the cell suspension was injected during 90 
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s balloon inflation and no-flow, followed by 5 min. reperfusion, and this procedure was 
repeated twice. 
 
Cardiac MRI 
Patients without contraindications underwent MRI 2-3 weeks (n=89), 6 months (n=93), and 
3 years (n= 88) after randomization. 1.5 T scanners were used (Magnetom Vision Plus 
(Siemens, Erlangen, Germany) for the first 18 months of ASTAMI, then Magnetom Sonata 
(Siemens) for the last 10 months of ASTAMI and the 3 year follow-up). Breath-hold cine-
sequences were obtained in 2-chamber, 4-chamber, and short-axis views with ECG-
triggered segmented gradient echo techniques for calculation of LV volumes and LVEF.  
LVEF = (EDV-ESV) / EDV 
Two different image processing protocols were used: Compact-FLASH (n=63) and true 
FISP (n=24, available with Magnetom Sonata, only). To avoid bias in serial evaluation of 
volumes, the same processing method was used for all acquisitions in each patient.  
LVEDV, LVESV, and LVEF were calculated by the biplane area-length method;  
V = (8 x A1 x A2) / (3 x  x L).56, 57      
Where V=volume, L=length (longest axis), A1 and A2 are the traced endocavitary areas.  
At 3 years, for comparison of methods, a stack of multiple short axis cine images were also 
recorded to calculate LV volumes by the Simpson method.56 
 
Where h= distance between centers of adjacent slices, n=number of slices, A1=area of the 
most basal slice, and An=area of the most apical slice. 
LV mass was determined from a stack of  short axis images covering the entire LV (slice 
thickness 7 mm, interslice gap 3 mm). Infarct size was determined from the short axis 
images 10-20 minutes after iv. injection of 0.2 mmol/kg gadopentetate dimeglumine 
(Magnevist®, Schering AG, Berlin, Germany) contrast medium. For this late enhancement 
contrast imaging, slice thickness was 8 mm, increment 10 mm, and in-plane spatial 
resolution was 1.17 x 1.17 x 1.5 mm. Myocardial- and infarct masses were calculated by  
multiplying volume with the tissue density 1.05 g/mL.58 A more detailed description of the 
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MRI processing and analyses can be found in the publication by Hopp et al. on a subgroup 
of patients from ASTAMI.59    
Echocardiography 
Transthoracic echocardiography was performed at baseline (4.5±1.1 days after AMI) and 3, 
6, 12, and 36 months after randomization, using a high-end cardiac ultrasound scanner 
(Vivid 7 with the M3S transducer, GE Vingmed, Horten, Norway). The recordings and 
analyses were performed according to general recommendations.60-62 LV volumes and 
ejection fraction (LVEF) were calculated by the modified Simpson method, tracing 
endocardial contours on apical 4-chamber and apical long-axis images. When 2 chamber 
images were of clearly better quality than the long-axis images, these were used.63 Tissue 
Doppler recordings were obtained from the apical 4-chamber view. Peak early diastolic (e’) 
velocities were registered in the septal and lateral mitral annulus, and mean values used for 
further calculations. Wall motion score was assessed by use of a segmental LV model, 
excluding the apical cap. All 16 segments were assigned a wall motion score (1=normal or 
hyperkinetic, 2=hypokinetic, 3=akinetic, 4=dyskinetic, and 5=aneurysmatic). The sum of 
scores was divided by the number of segments visualized, to obtain the wall motion score 
index (WMSI). Two-dimensional speckle tracking echocardiography (2D-STE) was 
performed in the standard 3 image planes acquired from the apex. Longitudinal (peak 
negative systolic) strain was measured to assess regional and global myocardial function in 
a 16 segment model of the left ventricle.64 As all patients in ASTAMI had LAD- related 
infarcts, the infarct zone was defined as the six segments schematically supplied by LAD. 
All other segments, schematically supplied by ramus circumflexus (LCX) and the right 
coronary artery (RCA), were defined as remote. Regional- and global strain were calculated 
as the average of all analyzed corresponding segmental strain values.65 Peak E- and A-wave 
velocities, and E-wave velocity deceleration time (DT) were measured, and E/A-ratio was 
calculated. Mitral A-wave duration was measured from flow recordings at the level of the 
mitral valve. Flow signals in the right upper pulmonary vein (pv) were obtained by low 
pulse repetition frequency (LPRF) Doppler from the 4 chamber apical view. Peak systolic 
(pvS)-, -diastolic (pvD)-, and -atrial reverse (pvA)- wave velocities and pvA wave duration 
were recorded, and the pvS/pvD-ratio was calculated. E/e’-ratio was calculated from peak 
early mitral inflow velocity (E) and peak early mitral annulus velocity (e’) in the apical 4 
chamber view. Except one patient with atrial fibrillation during the baseline recording, all 
patients were in sinus rhythm at all examinations. One patient in the control group had right-
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bundle branch block from baseline. One patient in the mBMC group developed left bundle 
branch block between 12 months and 3 years after inclusion. All analyses were performed 
offline on GE Echopac software, blinded to patient identity and treatment allocation. 
Cardiopulmonary exercise test 
Maximal symptom limited exercise tests were performed 2-3 weeks, 6 months, and 3 years 
after the AMI with an electrically braked bicycle ergometer (Jaeger ER900, VIASYS 
Healthcare GmbH, Hochberg, Germany). At 6 months and 3 years, betablockers, calcium 
channel blockers, and nitrates were postponed until after the test. Other medication was 
taken as usual. 10 minutes exercise time was pursued, starting at 25 or 50 W with 10 or 25 
W increase every second minute. For each patient the same protocol was used for every test. 
Oxygen consumption (VO2), CO2 production (VCO2), and ventilation (VE) were measured 
on a breath-to-breath basis (MVmax 229, VIASYS Healthcare GmbH, Germany). Heart rate 
and ECG were continuously recorded. Blood pressure was measured at the end of each step. 
For parameters sampled continuously or breath to breath, average values from 20 second 
time intervals were used in the analyses. Maximal VO2 and respiratory exchange ratio 
(RER) was measured in the last 20-second interval during exercise. The anaerobic threshold 
was defined as the VO2 at the point where ventilation started to increase exponentially 
compared to the increase in VO2. This point was determined by the V-slope method (using 
the VCO2/VO2-plot) whenever possible, and supplied by use of the VE/VO2-plot and the 
plot of end-tidal pO2 and end-tidal pCO2.66 The VE/VCO2-slope was determined by a linear 
regression analysis of all data obtained in the the VE/VCO2-plot during exercise.67 The  
MVmax 229 software was used for calculation. The oxygen uptake efficiency slope 
(OUES)68 was calculated by data from the second 20 –second time interval after start of 
exercise, data sampled at AT, and data at VO2 max. The slope was calculated as the best fit 
linear regression line relating log10VE and VO2 by use of Excel software (Microsoft, 
Redmond, WA). 
Blood biochemistry analyses 
Blood samples were collected by standard venipuncture between 8 and 9 AM after a 12-
hour fast. Serum was prepared by centrifugation within 1 hour at 2500 x g for 10 minutes. 
All blood biochemistry analyses in the 3 years follow-up were performed mainly for 
monitoring of safety, and were analyzed as routine samples at Department of Medical 
Biochemistry, Rikshospitalet. 
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Quality of life 
For assessment of health-related QoL, patients answered the Norwegian version 1.2 of the 
SF-36 health survey 2-3 weeks, 6 months, and 3 years after AMI. Scores were weighted and 
aggregated using normative data from the general Norwegian population to obtain physical 
component- and mental component summary scores. The calculations of weighted scores 
were performed by Torbjørn Moum, who also provided the normative data.  
 
Statistics 
Continuous data with approximated normal distribution were presented as mean±standard 
deviation. Independent sample t-tests were used to compare the groups at baseline. For 
analysis of continuous data measured at 	
	
		
regression analysis. Time and the interaction between treatment allocation and time were 
covariates. Treatment allocation was removed as a factor to adjust for differences between 
groups at baseline. Intragroup changes from baseline were evaluated by paired sample t-
tests. Continuous data with skewed distribution were presented as median (interquartile 
range), and Mann-Whitney tests were used for comparison between groups. Categorical data 
were presented as frequency (percentage) and Chi-Square or Fisher’s exact tests were used 
as appropriate. EpiData entry software version 3.1 and SPSS version 15.0 were utilized. All 
analyses were performed according to the intention-to-treat principle, tests were two-sided, 
and p-values <0.05 were considered statistically significant.  
Ethics 
The protocol was approved by the regional committee for research ethics and the study 
complies with the Declaration of Helsinki All patients gave written, informed consent. The 
ASTAMI study is registered at clinicaltrials.gov NCT 00199823.  
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Model, materials and methods 
(experimental study) 
 
Animals 
For an experimental model of stem cell therapy in acute or recent MI, several animal models 
can be considered. For the present study, the Institute of Immunology (IMMI) had well 
charachterized human MSCs available, thus a xenogenic model was needed to allow 
injection of human cells into animal hearts. Xenoimmune rejection of transplanted cells 
could jeopardize the potential for long term engraftment of transplanted cells. 
Immunodeficient strains of rats and mice are available, while concomitant 
immunosuppressive pharmacotherapy would be required if immunocompetent strains of rats 
or mice, or a larger animal like rabbit, dog or pig were used. The dosing of 
immunosuppressants would be unreliable if administered by oral feeding, and would be a 
significant stressor if administered by daily injections. Immunosuppressants would also 
potentially confound the results by modulation of the inflammatory response and/or 
remodelling after AMI, as described for calcineurin inhibitors.69 Mice are small, and the risk 
of unsuccessful myocardial cell-injection has been reported as high as 50 %.20 Based on 
these considerations, NiH rnu/rnu nude rats were used. The Rowett rnu-gene was a 
spontaneous mutation leading to a hairless, athymic, T-cell deficient phenotype in 
homozygous rats. The NiH rnu/rnu rats were developed in 1979-80 by adding and 
backcrossing the Rowett rnu-gene into eight inbred rat strains. Both Rowett and NiH 
rnu/rnu rats are in well established use for research in xenotransplantation.70, 71 The animals 
may acquire some cellular immunity with age, and it has been suggesteded that 
xenotransplantation should be performed before the age of 12 weeks to minimize risk of 
rejection. In our study, male NiH rnu/rnu rats and female rnu/+ rats (Charles-River, France) 
were bred at the Rikshospitalet animal facility by experienced staff, and rnu/rnu progeny 
were selected for use in our studies. Animals were maintained in a specific pathogen-free 
environment in positive pressure rooms with a standard 12 hour day/12 hour night cycle, 2-4 
animals per cage, with environmental enrichment. The animal department is subject to 
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regular microbiological testing. No significant pathogens were encountered in the rnu-rats 
during the period for our experiments. 
Cell processing 
A more detailed description of cell processing is presented in paper III. 
Isolation and culture of human skeletal muscle-derived MSCs (SM-MSCs) 
Skeletal muscle tissue was obtained from the gracilis and semitendinosus muscles removed 
from patients undergoing surgery of the anterior cruciate ligament. The donors provided 
written, informed consent, and the collection and storage of muscle tissue and SM-MSCs 
was approved by the regional committee for ethics in medical research. Ten to 20 g of 
skeletal muscle was washed, minced and digested in collagenase IA (Sigma), and 
resuspended in trypsin- EDTA (Sigma). The isolated cells were washed and subsequently 
cultured in DMEM/F12 containing 20% FBS, amphotericin B and antibiotics. Muscle cells 
were expanded up to P5 for two donors and P7 for one donor. CD56+ cells were removed 
using magnetic beads directly coupled to mouse anti-human CD56 monoclonal antibody 
(MAb) (Miltenyi Biotech, Bergisch Gladbach, Germany) and LS columns, leaving a CD56- 
population which has previously been described as MSCs.55 Cell viability was always 
>90%. Flow cytometry showed that no more than 3% of CD56+ cells were left in the 
suspension at P2 and last passage.  
Isolation and culture of human adipose tissue-derived MSCs (ADSCs) 
Adipose tissue (AT) was obtained as part of routine liposuction procedures from healthy 
donors. The donors provided written, informed consent, and the collection and storage of 
AT and ADSCs was approved by the regional committee for ethics in medical research. 
Lipoaspirate (300–1000 mL) was washed repeatedly with Hanks’ balanced salt solution 
(HBSS) (Life Technologies-BRL, Paisley, UK), and digested using 0.1% collagenase A 
type 1 (Sigma). After centrifugation, floating adipocytes were removed. The remaining SVF 
cells were resuspended in HBSS containing 2% FBS. Suspended cells were filtered through 
cell sieves (Becton Dickinson, San Jose, CA) and layered onto Lymphoprep gradient 
separation medium (Axis Shield, Oslo, Norway). After centrifugation, cells at the gradient 
interface were collected, and resuspended. ADSCs were separated from the remaining cells 
using magnetic cell sorting. Endothelial cells (CD31+) and leukocytes (CD45+) were 
removed using magnetic beads directly coupled to mouse anti-human CD31 and CD45 Mab 
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(Miltenyi Biotech) and LS columns. Flow cytometry showed that no more than 5% of 
CD31+ and CD45+ cells were left in the suspension. Cells were washed, resuspended and 
seeded in DMEM/F12 containing 20% FBS and antibiotics. ADSCs from 3 donors were 
expanded to P5. Prior to injection, cell viability was always >90%. 
Verification of the cells as MSCs by differentiation and flow cytometry studies 
To verify that the cultured cells were actually MSCs, SM-MSCs and ADSCs were 
differentiated along adipogenic and osteogenic lineages and analyzed by flow cytometry for 
MSC markers. For flow cytometric analysis, cells were incubated with directly conjugated 
antigen specific or irrelevant monoclonal antibodies (Mabs), and fixed in 1% 
paraformaldehyde. Mabs used were CD56/PE, CD105/APC, CD44/PE, HLA ABC/Cy-
Chrome, CD34/FITC, CD45/FITC (all BD Biosciences, CA), CD105/APC and HLA 
DR/APC (Diatec, Oslo, Norway), 144/PE (eBioscience, http://www.ebioscience.com/) and 
CD146/FITC (AbD Serotec, Kidlington, UK). Cells were analyzed using a FACSCalibur 
flow cytometer (Becton Dickinson).  
For adipogenic differentiation, confluent cultures were incubated in DMEM/F12 containing 
10% FBS, 0.5 μM 1-methyl-3 isobutylxanthine, 1 μM dexamethasone, 10 μg/mL insulin 
(Novo Nordisk, Copenhagen, Denmark), and 100 μM indomethacin (Dumex-Alpharma, 
Copenhagen, Denmark).  
 For osteogenic differentiation, cells were incubated at 3,000 cells per cm2 in DMEM/F12 
containing 10% AS or FBS, 100 nM dexamethasone, 10 mM ß-glycerophosphate, and 0.05 
mM L-ascorbic acid-2-phosphate.  
After 4 weeks, differentiated cells were examined by real-time (RT)-PCR and staining 
procedures. For real-time RT-PCR, total RNA was extracted from cells using Trizol reagent 
(Invitrogen, Carlsbad, CA). Following DNase treatment (Ambion, Austin, TX), RNA was 
quantified by spectrophotometry (Nanodrop, Wilmington, DE). Reverse transcription (RT) 
was performed using the High Capacity cDNA Archive Kit (Applied Biosystems, Abingdon 
U.K.) with 200 ng total RNA per 20 L RT reaction. Relative quantification (RQ) was 
performed using the 7300 Real-Time RT PCR system (Applied Biosystems) and Taqman® 
Gene Expression assays. All samples were scaled relative to the expression level of GAPDH 
(Taqman assay no Hs99999905_m1). For staining procedures, cells were fixed with 4% 
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formalin and subsequently incubated for 10 min with Oil-Red O and Alizarin Red S to 
visualize lipid droplets and calcium deposition, respectively.  
At the day of surgery and cell injection, cells were centrifuged, washed, and resuspended in 
DMEM with 10 % FBS at 20x106 cells/mL (3x106 cells/150!"

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stored on ice during transfer to the animal facility and injected within 2 hours. Immediately 
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approximately 37° C.  
Surgery and cell injections 
Rats aged 8-11weeks were anesthetized with 1% isoflurane, intubated, and ventilated by a 
rodent ventilator with 1% isoflurane in a mixture of 1/3 O2 and 2/3 N2O. A left thoracotomy 
was made at the fifth intercostal space, and the proximal portion of the left coronary artery 
was rapidly ligated by an intramural suture to induce anterior wall myocardial infarction.72, 
73 The chest was closed, subcutaneous Buprenorphine 0.05mg/kg was administered for 
analgesia, and animals were monitored for one hour after surgery. After 6 days, rats were 
sedated with 1.2 % Isoflurane inhalation and transthoracic echocardiography was 
performed. Animals with fractional shortening (FS) <25 % were selected for further studies 
as this cut-off identified  subjects with significant myocardial infarctions74, thus having a 
potential to benefit from regenerative therapy. The following day (day 7), animals were 
randomized to receive SM-MSCs, ADSCs or placebo (cell growth medium without cells). 
Sedation, intubation and anaesthetizia were performed as described. The chest was the 
#&	
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suspension or placebo was injected as 4 aliquots (3 in the border zone and one in the infarct 
zone), with a 30G needle. The chest was then closed and desufflated through an 18 G drain. 
Postoperative analgesia and monitoring as described above. Four weeks after cell injections, 
animals were weighed, repeated echocardiographies were performed. Animals were then 
euthanized, the hearts were harvested for histological analysis and the length of the right 
tibia was measured. 
Echocardiography 
Transthoracic echocardiography was performed on sedated animals in supine position with a 
Vivid 7 scanner and a 14 MHz Linear Array probe (GE Vingmed Ultrasound, Horten 
Norway). As both parenteral and gaseous anaesthetics induce changes in LV pre- and 
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afterload, reduce contractility and even cause LV dilatation, a low dose of isoflurane was 
used (1.2 %), and rapid image acquisition was pursued. Parasternal long axis and 2 short 
axis cine loops (midpapillary and basal) were aquired. M-mode registration (LV wall 
thickness, endocavitary diameter, and FS) was aquired in the midventricular level (figure 2). 
LVEF was calculated by the area-length  method from the long-axis cineloop (figure 3a). 
We also calculated a wall motion score index in a 13 segment model using the long axis- 
and two short axis cineloops (figure 3b).75 All analyses were performed blinded to treatment 
allocation. Measurements were performed on three consecutive heart-cycles and averaged. 
Figure 2. M-mode echocardiograms. 
 
M-mode echocardiograms from one MSC treated animal at baseline and 4 weeks after cell injection. Wall 
thickening both in the septum and in the posterior wall has improved, but som dilatation of the left ventricle 
has occurred. 
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Figure 3a. LVEF by area- length  
  
Parasternal  long-axis image with superimposed area-length tracings for calculation of LVEF 
 
Figure 3b.  
 
The 13 segment model of the murine left ventricle, based on parasternal long-axis and two parasternal short- 
axis cineloops.  
 
Histological preparation 
After explantation, hearts were fixed in phosphate-buffered formalin (4%) for 24 hours, cut 
in 4 mm slices, dehydrated, and embedded in paraffin. Random hearts in each group were 
selected for assessment of infarct size and vascular density. Hearts were cross-sectioned in 3 

"	
Leica microtome to obtain a stack of short-axis slices covering the entire 
left ventricle with 1 mm gap between slices for assessment of both infarct size and vascular 
density. 
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Infarct size 
For estimation of infarct size, sections were stained with Masson Goldener (trichrome), 
according to the standard procedyre in the Department of Pathology, Rikshospitalet. Masson 
Goldener stains collagen green and viable myocardium stains red, as illustrated in figure 4a. 
Microscopy was performed by pointcounting images collected at 12.5 x magnification with 
a randomly superimp
@?@?	intersections on the grid were 
recorded as hits on the  infarct zone or not, as illustrated in figure 4b. The percentage infarct 
area on each section was determined by the number of infarct zone intersections on the grid 
divided by the total number of intersections. The sum of scores for all slides covering the 
entire LV was used to estimate the total infarct.76 The entire interventricular septum was 
counted as a part of the left ventricle. The pericardial zone and the right ventricle was not 
included in the analysis. An Olympus microscope with AnalySIS software (OlympusSIS, 
Münster, Germany) was used for morphometry. 
Figure 4a.  
 
Cross section of a murine heart stained with Masson Goldener. The green collagen staining indicates a large 
myocardial infarction. 12.5x magnification.  
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Figure 4b.  
 
The image in 4a after pointcounting with green markers (non-infarcted left ventricle) and blue markers (infarct 
zone) on a superimposed grid. 12.5x magnification. 
Vascular density 
To assess vascular density, sections were stained with goat anti-VE Cadherin primary 
antibodies (R&D Systems, Minneapolis, MN), biotinylated rabbit anti-goat secondary 
antibodies (DAKO, Glostrup, Denmark)), and streptavidin peroxidase. Hematoxylin was 
used for contrast staining (figure 5). Microscopy was performed on images collected with 
400 x magnificati??&
	
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the infarct zone (scar tissue), borderzone (granulation tissue), and remote myocardial 
segments were counted on 6 representative sections from 10 random animals in each group. 
The fields were selected according to a prespecified system for localization on the slide, in 
order to reduce potential bias. The number of intersections affecting vessel lumen and -wall 
was divided by the total number of intersections in the relevant tissue on the slide to obtain 
the density of VE Cadherin positive vessels (figure 6)\
[
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were rare events in the myocardium and in the scar tissue, these were not included in the 
analysis.  
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Figure 5.  
 
Normal myocardium with anti VE-cadherin and hematoxylin staining for calculation of vascular density. 400x 
magnification. 
 
Figure 6.  
 
Borderzone with VE-cadherin staining and superimposed grid for calculation of vascular density. Blood 
vessels marked with blue circles. 400x magnification. 
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Borderzone quantification 
The borderzone was defined as the potential area between the scar tissue and the 
myocardium. In our study, the borderzone was characterized by the presence of granulation 
tissue (figure 7a and 7b). Granulation tissue was defined as loose connective tissue, rich in 
small blood vessels and free from cardiomyocytes or collagenized scar tissue. To quantify 
the granulation tissue in the borderzone, we obtained one 100 x image from the borderzone 
on both sides of the infarction (both sides of the infarcted sector of the circumference). 
Granulation-tissue was quantified by morpho	"&
	
??
superimposed grid, pointcounting granulation tissue (hits) and other cardiac tissue (non-
hits), as previously described. The pericardial zone and the right ventricle were not included 
in the analysis. 
Figure 7a.  
 
Image from the borderzone in a heart from the MSC group. 100x magnification. 
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Figure 7b.  
 
Image from borderzone in a heart from the placebo group. 100x magnification. 
 
In situ hybridization 
For identification of the transplanted cells, we performed fluorescence in situ hybridization 
(FISH) with a fluorescein isothiocyanate (FITC)- conjugated probe specific for the human 
ALU- sequence (Alu positive control probe, Ventana, Tucson, AZ) on sections incubated in 
a Ventana discovery machine according to the manufacturer’s instructions. For initial cell 
tracking, the fluorescent ALU- signal was amplified by incubating the slides overnight with 
Alexa 488 conjugated mouse anti-fluorescin antibody (Millipore, Billerica, MA), as 
illustrated in figure 8. On slides used for differentiation staining, the ALU-signal was not 
amplified.   
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Figure 8.  
 
Infarct zone stained with FITC conjugated ALU-probe (green human DNA) and 4',6-diamidino-2-
phenylindole (DAPI) (blue cell nuclei). 600x magnification. 
 
Immunofluorescence staining 
Tissue sections with Alu-positive cells were counterstained with myocardium-, smooth 
muscle-, and endothelium-specific antibodies. Primary mouse anti-human Mabs specific for 
anti-smooth muscle actin (SMA, Dako), anti-desmin (Dako), anti-CD 31(Dako), and anti-
Nkx 2.5 (R&D Systems), and Alexa 555-conjugated anti-mouse secondary antibodies 
(Molecular Probes, Eugene, OR) were used. We also applied rabbit anti-Troponin I primary 
antibody (Abcam, Cambridge, UK) with biotinylated goat anti-rabbit (Vector Labs, 
Burlingame, CA) and Alexa 594-conjugated streptavidin (Molecular Probes). Nuclei were 
stained with DAPI. Sections from human hearts and hearts from rats in the placebo group 
were used as positive and negative controls, respectively. Multiplane fluorescence 
microscopy was performed on a Zeiss Axioplan 2 microscope (Göttingen, Germany) with 
ISIS software (Metasystems, Altlussheim, Germany). All image analyses were performed 
blinded regarding treatment allocation. 
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Figure 9 a-d.  
Tissue sections from a heart treated with SM-MSC injections. All sections stained with 
DAPI (blue nuclei), FITC conjugated Alu-probe (green and blue nuclei). Additional 
antibodies with red fluorescence against markers of differentiation as described for 
each image 
Figure 9a. 
 
Human troponin I. (Transplanted cells detected, but no human troponin I). 600x magnification. 
 
Figure 9b.  
 
CD 31. (No human cells detected) 600x magnification. 
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Figure 9c. 
 
SMA. (No human cells identified. The small green signals are RBCs (autofluorescence)). 200x magnification. 
 
Figure 9d. 
 
Desmin. (No human cells identified. The small green extranuclear signals are RBCs (autofluorescence)). 200x 
magnification. 
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Statistics 
Baseline characteristics were presented as mean±standard deviation (SD) for all animals 
included in the study. Follow-up characteristics were presented for all animals surviving to 
follow-up. Change in characteristics was calculated only for animals surviving to follow-up. 
All continuous data were analysed by one-way ANOVA with Bonferroni correction for 
multiple comparisons in the post-hoc analyses. Categorical variables were analysed by Chi-
square tests. SPSS software version 15.0 and 16.0 was used.  
 
Ethics 
Skeletal muscle and adipose tissue were obtained from voluntary human donors after 
written, informed consent. The collection and storage of samples and cells were approved 
by the regional committee for ethics in medical research (approval number 1.2006.740 and 
2.2007.132, respectively). The use of animals was approved by the National Animal 
Research Authority, and animals were handled in accordance with the Norwegian Animal 
Welfare Act and the Norwegian Regulation on Animal Experimentation. 
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Summary of the results 
Paper I: Data from the 3 year follow-up of patients in the ASTAMI study were presented. 
The rates of adverse clinical events were low, and did not differ between groups. By MRI 
and echocardiography, no difference was found between groups in LV volumes, LVEF or 
infarct size at any point of time, and the change over time was also similar. Infarct size 
measured by MRI decreased significantly in both groups during the 3 years of observation. 
On exercise testing, we found a larger improvement from baseline to 3 years in exercise 
time in the mBMC group as compared to the control group. Similar results were found after 
6 months. No differences between groups were observed for other parameters on exercise 
capacity, including the predefined endpoint peak VO2. On the SF 36 QoL questionnaires, 
the patients reported perceived physical and mental health status in close range to age-
adjusted healthy normal population, and there was no differences between the groups. Blood 
biochemistry analyses did not reveal significant abnormalities, median pro- BNP level was 
within the normal range, and there were no significant differences between the groups. 
 
 
Paper II: Data from a comprehensive analysis of echocardiographic data aquired during 3 
years follow-up of the ASTAMI pasients were presented. Transthoracic echocardiography 
was performed at baseline, 3,6,12 months and 3 years. From baseline to 3 years, LV ejection 
fraction changed from 45.7 % to 47.5 % in the mBMC group, and from 46.9 % to 46.8 % in 
the control group (p=0.87 for difference in change over time between groups). Longitudinal 
strain in the LAD territory improved from -9.7 % to -12.2 % in the mBMC group and from -
9.9 % to -12.8 % in the control group (p=0.45). WMSI also decreased significantly in both 
groups. E/e’ decreased from 14.7 to 12.9 in the mBMC group and from 14.8 to 11.9 in the 
control group (p=0.31). In both groups, there was significant decrease in peak E, increase in 
peak A and increase in DT, all indicating a decrease in filling pressure during the 3 years 
follow-up. 
The results indicated improvement in both regional and global systolic LV function and 
diastolic LV function during 3 years follow-up after AMI. No significant differences 
between groups indicating any effect of mBMC therapy was observed, even when a new 
and more sensitive methods like 2D-STE was applied.  
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Paper III: MSCs from skeletal muscle (SM-MSCs) and adipose tissue (ADSCs) were 
injected in the myocardium of nude rats one week after myocardial infarction. After four 
weeks of observation, LVEF was significantly improved in the SM-MSCs group 
(39.1±9.7%), and in the ADSC group (39.6±6.8%), compared to the placebo group 
(31.0±8.3%, P<0.001 for difference in change between groups). Infarct size was smaller 
after cell therapy (16.3±4.0% for SM-MSCs, 15.8±4.9% for ADSCs vs 26.0±6.8% for 
placebo, P<0.001), and the amount of highly vascularized granulation tissue in the 
borderzone was significantly increased in both groups receiving MSCs (18.3±3.7% for SM-
MSCs, 22.6±6.0% for ADSCs vs 13.1±5.3% for placebo, P=0.001). By in situ hybridization, 
moderate engraftment of transplanted cells was found, predominantly in scar tissue close top 
the borderzone. No transdifferentiation to cardiomyocytes, endothelial cells, or smooth 
muscle cells was observed. 
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Discussion 
This thesis demonstrates that intracoronary injection of mBMCs in patients after acute 
anterior wall myocardial infarctions is feasible and probably safe in a 3 years perspective, 
but significant beneficial long term effects on predefined endpoints like LVEF, infarct size, 
peak oxygen consumption, and quality of life were not found. In the experimental study 
using a xenomodel with human cells transplanted into nude rats, we found that MSCs 
harvested from both adipose tissue and skeletal muscle were able to engraft in the heart and 
significantly improve LVEF when the cells were injected intramyocardially one week after 
myocardial infarction. Infarct size was reduced, but the injected cells did not differentiate to 
cardiomyocytes.  
 
Methodological considerations, clinical study 
The present study was a prolonged follow-up of patients in the ASTAMI study. As the long- 
term follow up was not part of the original protocol, the results should be considered 
exploratory. We have used the same methods for data collection at 3 years as in the original 
protocol, to be able to perform analyses of longitudinal changes in addition to cross-
sectional comparisons between groups. We also used the same parameters as primary 
endpoints to reduce the risk of type I errors by multiple testing. ASTAMI was a phase II 
study evaluating efficacy, safety and feasibility of intracoronary mBMC injections in acute 
AMI. The sample size was inadequate for efficacy testing on clinical endpoints, and change 
in LVEF was used as the primary surrogate endpoint. For exercise testing, change in peak 
MVO2 was selected as the predefined endpoint. Several issues regarding the original 
protocol have been discussed in previous publications.24-26, 28 In the current discussion, 
issues unique for or most relevant for the long term follow-up are emphasized. 
Internal validity: To avoid selection bias, the ASTAMI-study was designed as a 
randomized study, and all analyses in the study were performed according to treatment 
allocation (intention to treat). At baseline, no significant differences between groups were 
found. In the linear regression model applied for analysis of longitudinal change in 
parameters with multiple (>2) observations, adjustment for baseline value was included in 
the model to minimize eventual impact of small (random) differences between groups at 
baseline. For the same reason, ANCOVA was used for comparison between groups when 
paired data were available. One patient originally included in the study and randomized to 
 41 
the control group experienced an early myocardial reinfarction with cardiogenic shock. The 
patient underwent cardiac transplantation and was excluded from the study at day 11, as 
data on the primary endpoint, change in LV- function, were no longer available. Another 
patient in the control group was not willing to participate in the 3 years follow-up. The 
patient did not withdraw consent for the original study. The patient has been registered as 
alive at 3 years, but no further data are registered at 3 years and values from the 12 months 
follow-up have not been carried forward. The exclusion of a patient with early reinfarction 
contribute to the low rate of clinical events in ASTAMI, but the loss of 2 (potential) clinical 
events from the control group would not significantly alter the conclusion in the study (data 
not shown).  
Regarding information bias, ASTAMI was an open labeled study. Sham bone marrow- 
harvesting and cell-infusion was not performed. Thus, all patients and some of the 
investigators were aware of the treatment allocation. This may potentially have influenced 
the registration of clinical events, the patients reporting of quality of life in the SF-36 
questionnaire, and also the performance during cardiopulmonary exercise testing. Objective 
parameters like peak heart rate and respiratory exchange ratio (RER) did not indicate 
significant difference in efforts between groups during exercise, but we did find a 
significantly better improvement in exercise time and heart rate recovery in mBMC treated 
patients despite no difference between groups in the increase of peak VO2.  A placebo 
effect, or information bias, may possibly explain this observation, as exercise time, but not 
peak VO2 or maximum heart rate, can be improved by extended efforts at maximum 
exercise. Peak VO2, and not exercise time, was selected as the primary measure for exercise 
capacity in ASTAMI. According to the considerations on bias, prognostic value, preselected 
endpoints and the risk of type I errors due to multiple testing, the difference between groups 
in change in exercise time was not emphasized. In general, at the 3 years follow-up, 
parameters at obvious risk for subjective influence were similar between groups and 
corresponded with data from more objective measures. After publication of the results from 
the 6 months follow-up, patients were aware of the neutral treatment effect. Thus, neither 
patient information nor collected data suggest significant information bias. All analyses of 
echocardiograms, MRI, SPECT, laboratory specimens, SF-36 questionnaires, and results 
from cardiopulmonary exercise testing were performed by observers blinded to treatment 
allocation and blinded to results from other tests.  
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Performance of measurements: 
-Clinical endpoints: In the ASTAMI study, clinical endpoints were registered to monitor the 
safety of this novel treatment modality. As tabulated in paper I, the rate of clinical events 
was low in ASTAMI, and there was no significant difference between groups. Patients were 
monitored regularly, and all clinical events were registered in the case report form (CRF). 
Only one patient, in the control group, dropped out of the study. Injected mBMCs were not 
labeled, and patients were not tested for systemic embolization of mBMCs. Patients were 
not scanned for silent infarctions in common sites for cardiac embolization (brain, kidney, 
spleen, liver). However, no patient had clinical symptoms or changes in biochemical 
markers indicating extracardiac embolic or ischemic events related to cell therapy. 
Procedure related myocardial infarction or subsequent reinfarctions were diagnosed 
according to current guidelines.77 Other clinical events were registered based on routine 
evaluation by the investigator. All adverse events were reported to the independent data 
safety and monitoring board (DSMB) for evaluation. With an open-label design, awareness 
of treatment group may potentially influence the reporting of clinical events. However, 
despite low event-rates, we have no indications for biased reporting of adverse events in 
ASTAMI. In a study with 100 included patients and low rate of clinical events, it is 
important to underscore that there is not sufficient statistical power to evaluate treatment 
efficacy on clinical endpoints, implicating that we can neither reliably conclude that the 
treatment is safe, nor rule out a potential clinical benefit of mBMC therapy.  
 
Left ventricular function: The primary endpoint in ASTAMI was the change in LVEF from 
baseline to 6 months by SPECT. At the 3 years follow-up, we evaluated the risk-benefit 
relation for every examination in the original protocol, and did not perform coronary 
angiography or radionuclide scans.  
Cardiac MRI was performed at 3 years, and provided supplementary data regarding infarct 
size and safety, as tumor formation and calcification has been reported as potential side 
effects after mBMC therapy. Regarding LVEF by MRI, a complete dataset after 3 years was 
available in 84 patients. Thus, 13 patients had contraindications or missed the baseline 
recording due to logistic problems. The baseline MRI scans were performed 2 weeks after 
mBMC injections. Thus, eventual effects of mBMC therapy appearing earlier than 2 weeks 
after injection would not be detected and reflected in the MRI data. The late enhancement 
imaging was cancelled in one patient at 3 years due to reduced renal function, as the 
potential risk for nefrogenic systemic sclerosis with use of Gadolinium contrast agents had 
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been further acknowledged at this time. The MRI dataset was also limited by the use of old 
MRI scanners (Magnetom Vision Plus) and the Compact-FLASH (n=63) processing 
protocol in the first included patients. These images had poorer image quality, resulting in 
higher interobserver variability compared to analyses performed with new equipment and 
new processing protocols (Magnetom Sonata and True FISP), as illustrated in figure 10. 
Furthermore, LVEF has been calculated by the biplane area length method on 2-chamber 
and 4-chamber cine images. The current gold standard for calculation of LVEF is the 
Simpson method based on a stack of multiple short-axis cine images covering the entire left 
ventricle. Although a comparison of the 2 methods published before ASTAMI indicated 
high correlation56, the biplane method carry risk of foreshortening compared to the true 
length axis of the ventricle. The image planes may also vary between different examinations 
in the same patient, leading to variability especially in patients with regional myocardial 
dysfunction. At the 3 year follow-up, both short-axis and long-axis cine-images were 
acquired, and data for comparison are presented in table 2.  
 
Table 2.  
 Short-axis method (mean± SD) 
Area-length method 
(mean± SD) 
Difference 
(mean± SD) 
Intraclass 
correlation 
EDV (mL) 175±63 164±61 12±17 0.96 
ESV (mL) 86±54 78±48 7±13 0.98 
LVEF (%) 54±13 55±12 -0.6±6.3 0.87 
Comparison of the area length method and the multiple short-axis Simpsons method for calculation of LV 
volumes and LVEF by MRI. 
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Figure 10.  
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Bland-Altman plots for MRI interobserver variability with Compact FLASH and True FISP processing 
protocols. Illustration from the thesis “Treatment of acute myocardial infarction with intracoronary 
administration of autologous bone marrow cells”. Ketil Lunde. University of Oslo, 2007. ISBN 978-82-8072-
762-6. Reused with permission. 
 
As illustrated, the correlation between the 2 methods is excellent for LV volumes, and good 
for LVEF. Both EDV and ESV are systematically larger when calculated by the multiple 
short-axis method, and the main reason is probably foreshortening when the area-length 
biplane method is applied. It is important to acknowledge that although LVEF by the two 
methods correlate by less than 0.9, the mean estimates by the two methods for LVEF in the 
patient cohort differ by only 0.6 %. A Bland-Altman plot (not shown) indicates symmetric 
variance along the entire spectrum of ejection fractions measured in the study. This 
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indicates that the use of the area-length method for calculation of LVEF in ASTAMI did not 
introduce drift or bias as compared to the gold standard multiple short-axis method.  
MRI is considered more precise than echocardiography in test-retest evaluation of LVEF.78-
80 Due to limitations regarding the timing of the first MRI recording, the MRI data in our 
population may not accurately reflect the effects of mBMC therapy from baseline, but 
should be considered more precise than echocardiography in evaluation of changes in LV 
volumes, LVEF, and infarct size between 2 weeks and 6 months, and between 6 months and 
3 years.  
Transthoracic echocardiography was performed at baseline, 3,6,12 and 36 months. The 
baseline recording was performed 4.5±1.1 days after AMI, i.e. 1-2 days before cell 
injection. As the first MRI scans were performed approximately 2 weeks after cell injection, 
the change in LVEF by echocardiography remains the most reliable endpoint for effects of 
mBMC therapy on LV function in our 3 years follow-up.  2D-STE analyses were performed 
by Ola Gjesdal (OG, n=49) and Jan Otto Beitnes (JOB, n=51). 2D-STE analyses were 
performed by the same observer at all timepoints to eliminate interobserver variability in 
change in strain over time. All other echo-derived data are based on analyses performed by 
Ketil Lunde (KL) at baseline, 3, 6, and 12 months, while JOB performed the analyses at 3 
years. As the same observer analysed recordings from both groups at each point of time, 
while the observer was replaced between 12 months and 3 years, evaluation of interobserver 
variability was emphasized. Interobserver variability between KL and JOB was tested by 
JOB reanalyzing a random sample of 25 echocardiograms from the 6 months follow-up. 
Results are presented in table 3 and figure 14 a-d. Interobserver variability on global strain 
between OG and JOB was tested by JOB reanalyzing a random sample of 25 
echocardiograms from the 6 months follow-up. The difference between observers was 
0.75±0.22 %.  
 Table 3. Interobserver variability. Standard echocardiography. 
 KL 
(mean± SD) 
JOB 
(mean± SD) 
Difference 
(mean± SD) 
Intraclass 
correlation 
EDV (mL) 149±49 147±45 -1±14 0.96 
ESV (mL) 79±31 77±32 -1±8 0.97 
LVEF (%) 48±10 49±8 1.1±4.9 0.85 
WMSI 1.58±0.21 1.61±0.25 0.04±0.13 0.83 
These interobserver analyses confirm that variability between observers was acceptable. 
Bias was only 1 mL for LV volumes and 1 % for LVEF. Standard deviations were also low 
enough to assume that level of statistical power was maintained. 
 
External validity 
The result in ASTAMI differs from REPAIR-AMI, where the event rate was higher and 
there was a significant reduction in major adverse cardiovascular events (MACE) in the 
mBMC group after 1 year, as compared to placebo. The mortality in ASTAMI also differs 
from clinical registry data, i.e. 30 day mortality after ST-elevation AMI was 11.1 % in the 
European Heart Survey (EHS) in 2004.81 Most clinical trials will recruit patients with low 
comorbidity and high compliance with the study protocol and other advice, to reduce noise 
in the dataset. Thus, the risk of adverse clinical events will often be lower than observed in 
the registries. This selection of patients may reduce the external validity of the study, i.e. 
whether the results from the study can be extended and applied in a general patient 
population.   
Table 4 illustrate selected characteristics of patients in ASTAMI compared to patients from 
other studies; ASTAMI and REPAIR-AMI are mBMC studies, HORIZONS- AMI82 is a 
contemporary study on patients with acute STEMI comparing different types of stents and 
antithrombotic therapy in the cath- lab, Europeans heart survey (EHS 2004) is an European 
registry from selected hospitals. 
The data in Table 4 can, to some extent, clarify why mortality in ASTAMI was low despite 
large anterior wall ST- elevation myocardial infarctions. In ASTAMI, 1608 patients 
admitted to RH and UUS in the study period with ST-elevation myocardial infarctions were 
screened for participation. 718 patients were excluded due to RCA or CX related 
infarctions, 646 did not match inclusion/exclusion criteria (comorbidities etc), 50 patients 
were reluctant to participate, and 93 were ineligible due to logistical considerations. Patients 
in ASTAMI were younger and had lower prevalence of risk factors than patients in the 
EHS. It should also be noticed that the medical therapy in ASTAMI adhered absolutely to 
current guidelines, while compliance was slightly lower in both REPAIR, HORIZONS-AMI 
and in the EHS. In addition, two patients in ASTAMI were successfully resuscitated after 
in-hospital cardiac arrest during protocolled extended hospitalization (day 7-10).  
The table also illustrates that patients in the clinical studies represent selected subgroups in 
comparison to the general AMI population. In the EHS, only 70 % of patients presenting 
with ST- elevation AMI underwent coronary angiography. Patients in the mBMC studies 
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were > 5 years younger and had fewer risk factors and lower comorbidity as compared to 
patients in the EHS. Characteristics of the 1608 patients screened for ASTAMI were also 
different from the registry (data not shown). The majority of patients screened at UUS and 
RH were referred from other hospitals. This may indicate that patients transferred to UUS 
and RH for acute PCI had already been subject to some selection. Thus, the results in 
aforementioned clinical trials can probably be extended to most patients with STEMI 
referred to acute PCI, but not to all patients presenting with AMI. 
 
Table 4   
 ASTAMI REPAIR-AMI HORIZONS-
AMI 
EHS 2004 
Age (y) 57.4 ± 9.0 56 ±11 59.6 62.5 ± 13.1 
Women (%) 16.0 18.0 23.5 25.9 
History of previous CABG (%) 0 na# 2.1 
8.9 
History of previous PCI (%) 9 na 8.6 
Previous AMI (%) 4# na# 10.0 15.7 
Hypertension (%) 34.0 57.0 51.6 50.0 
Renal failure (%) 0.0 0.0 15.5 3.8 
Diabetes mellitus (%) 9.0 17.0 15.7 21.4 
Anterior ST- elevation 
myocardial infarction (%) 
100.0 70.0 41.0 na 
Baseline LV function (%) mean LVEF 
46.3 
mean LVEF  
47.1 
median 
LVEF 50 
na 
Mortality (%) 0  
(6 months) 
3.9 
(4months) 
3.5 
 (1 year) 
7.2 
(30 days) 
Aspirin (%) 100.0* 97* 98* 97* 
Betablocker (%) 100* 94* 92* 83* 
Statin (%) 98* 93* 96* 81* 
ACE-inhibitor/ARB (%) 100* 97* 83* 75* 
†mediaction at 6 months in ASTAMI, 4 months in REPAIR-AMI, at discharge in HORIZONS-AMI and in- 
hospital in EHS. na= not available 
# Comprehensive descriptions of prevalence and in-/exclusion of previous AMI, PCI and CABG are not 
specified in the publications or protocols. In ASTAMI, patients with previous Q-wave infarctions were 
excluded, and previous PCIs and non-Q infarcts were registered. Such data from Repair-AMI were not 
published, but it can be presumed from objective and design of these studies that the prevalence of these 
conditions was low.  
 
 
 48 
Comparison with other mBMC studies 
The majority of studies investigating the effects of mBMC therapy in AMI have included 20 
to 200 patients, followed the patients for 4-6 months and used change in LVEF as the 
primary endpoint. Clinical events have been registered for evaluation of safety, as sample 
size has been inadequate to conclude about effects on clinical endpoints. As seen in table 1, 
the BOOST and REPAIR-AMI studies demonstrated a statistically significant improvement 
in LVEF 4-6 months after mBMC- therapy. The other major trials did not provide positive 
results on the primary endpoint, but there is an overall trend suggesting larger improvement 
in LVEF in patients treated with mBMCs. This is also reflected in the metaanalysis by 
Martin-Rendon et al, where an average treatment-effect of 2.99% on LVEF was found after 
mBMC- therapy.34 However, it should be noted that the large REGENT83and HEBE84 
studies, which both failed to prove significant benefit of mBMCs, were published after this 
metaanalysis and are therefore not part of the data basis. Furthermore, at least 2 other 
studies on mBMC treatment in AMI have been prematurely terminated based on negative 
preliminary results.37, 85 Only few studies have presented data from follow-up beyond 12 
months. In the initially positive BOOST trial, no positive effect of mBMC therapy on LVEF 
could be detected after 5 years, and the rates of clinical events were similar in the two 
groups.86 From the REPAIR- AMI study, where single-plane angiocardiography was used to 
evaluate LV function at baseline and after 4 months, extended follow-up of LV- function 
has only been presented from a subgroup of 54 patients included in a substudy with cardiac 
MRI at baseline, 4 months and 12 months.87 In this substudy, the groups were small, and 
although the numeric results corresponded well with findings by angiography at 4 months, 
there was no significant difference in treatment effect between groups. Thus, the neutral 
result after 3 years in ASTAMI is not in conflict with long term follow-up data from other 
studies. 
The neutral result in ASTAMI and the positive result in REPAIR-AMI after 4 months have, 
by some, been regarded conflicting results. Thorough investigations were initiated to 
identify explanatory differences in protocols and methods. The underlying assumption has 
been that the cell product in ASTAMI was impaired as compared to cells used in REPAIR-
AMI. One study suggested that cell separation by Lymphoprep yielded fewer cells than 
centrifugation with Ficoll-Paque (Cambrex), and that storage of mBMCs in Heparin-plasma 
lead to reduced migratory capacity against SDF-1 gradient in vitro, as compared to storage 
in X-VIVO 10 (Cambrex).30 However, this study was conducted by members of the 
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REPAIR-AMI study group, and has to date not been reproduced by others. Another study, 
by members in the HEBE group, found similar yield of cells with the use of Lymphoprep 
and Ficoll paque, and suggested that low sentrifugation speed and loss of cells in the 
supernatant could explain a low yield of cells in ASTAMI.88 However, this study did not use 
the actual ASTAMI centrifugation protocol, and in ASTAMI it was checked that the 
supernatant did not contain cells. It has also been suggested that red blood cells (RBCs) in 
the cell product will reduce its clinical efficacy.89 This has not been prospectively addressed 
in any clinical study, and the gelatine-polysuccinate density gradient sedimentation method 
applied to isolate BMCs in the initially positive BOOST-study, yield a cell product with a 
relatively high content of polynucleated white blood cells (WBCs) and also quiet a few 
RBCs. Thus, details in cell preparation may be of importance, but the findings in these post-
hoc studies remains controversial and should be prospectively evaluated in clinical trials. 
With time, several larger studies with well characterized cell products have failed to prove 
significant effects of mBMC therapy. Meta- analyses have found overall treatment-effects 
around 3 % on LVEF.34 In REPAIR-AMI, the treatment effect was 2.5 %. ASTAMI was 
designed with 80 % power to detect a treatment effect of 5% on LVEF by SPECT. Thus 
ASTAMI was not powered to detect the modest beneficial effects on LVEF found in some 
other trials, and is as such not in conflict with other evidence. Furthermore, the beneficial 
effect of mBMC therapy seems limited as most trials fail to meet their primary endpoint. 
 To summarize, small to medium sized clinical trials suggest a treatment effect on 
LVEF within the range 0-3 % when autologous mBMCs are harvested and injected 
approximately 1 week after AMI. The procedure is considered safe, based on summarized 
clinical endpoints in the meta-analysis.34 Whether the modest effect on LVEF eventually 
translates into a significant reduction in mortality, is not clear. In the REPAIR-AMI study, a 
significant improvement in clinical outcome was observed after 1 year.90 This was not the 
primary endpoint, and the result was mainly caused by a high rate of coronary events in the 
placebo group, as discussed elsewhere.33 A pan-European initiative to run a prospective 
randomized trial with 3000 patients and statistical power to address effects on clinical 
endpoints is in progress (The BAMI trial, prof. A. Mathur, personal communication). 
 
Methodological considerations, experimental study 
LV function: We used transthoracic echocardiography for evaluation of LV function. Image 
quality allowed tracing of endocardial contours and wall motion scoring in all animals. 
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In our department, LV fractional shortening (FS) has been the most frequently used 
parameter for evaluation of LV function in heart failure studies in rats. Time resolution with 
M- mode imaging is high, which is advantageous when heart rate (HR) is high. However, 
FS is measured at the midventricular level (tip of the papillary muscle) and the 
posterolateral segment will not be infarcted after LAD- ligation while the mid-septal 
segment will be variably affected depending on coronary anatomy in different animals. 
Thus, the measurements of FS may have been performed in infarct zone, border zone or 
normal myocardium, depending on infarct size and localization after LAD- ligation. FS 
measurements reflect changes of LV-dimensions along one tangential line in a single plane. 
This method can be fairly accurate for conditions with uniform influence on the 
myocardium, while conditions with regional changes in LV function can be misjudged. 
According to the limitations of the FS- method, and the regional nature of both the ischemic 
lesion and the stem cell injections, we also measures LV systolic function by area-length 
derived LVEF and wall motion scoring.  
The area- length-method for estimation of LVEF has been used for over 50 years and is 
based on tracing of endocardial contours and estimation of the LV length axis on 2D images 
at the end of diastole and the end of systole.91, 92 In our study, parasternal long-axis images 
were used. ECG was not registered, and frames with the smallest and largest areas during 
the heart cycle were used. A representative image with trace is presented on page 28, and 
the formula for calculation of volume by area-length is presented on page 19. Although this 
method also estimated LV–function by analysis in a single plane, both radial and 
longitudinal dimensional changes in segments including the infarct zone were invariably 
included in the measurement. The other main limitation is framerate. The obtained 
framerates on 2 D images were in the range 105-200 s-1, depending on the size of the sector, 
and HR was 394±42 min-1 during baseline recordings and 392±35 min-1 after 4 weeks. 
Thus, approximately 15-35 frames/cycle were obtained. As dV/dt is close to 0 at the end of 
diastole- and - systole, framerates at this level will introduce only modest variability in 
calculation of LVEF. At the baseline study, FS and LVEF correlated with Pearson R 0.63, 
p<0.001.  
Wall motion scoring is a semiquantitative visual estimation of change in wall thickness. In 
humans, the method is accurate for estimation of LV function and prognisis, especially in 
regional processes like AMI.93 In the rat, apical images are not easily obtained without 
foreshortening. Morgan et al has validated a 13 segment model for WMSI in rat.75 We 
slightly modified this model (rotation of the segments in short axis view for better 
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correspondence between short-axis and long axis segments), and applied it for estimation of 
a WMSI in our study. The main limitation was reduced visualization of medial and apical 
segments in some rats. Wall motion scoring may also lack sensitivity for changes in the 
degree of hypokinesia, and it may also be difficult to reflect changes in the extent of 
akinesia within a segment, as the scar volume contracts over time.  
For all parameters on LV function measured during general anesthesia or sedation, 
cardiodepressive pharmacological effects will play a role. Inhalation of isoflurane provides 
rapid onset, easy adjustment and immediate recovery of the sedative effect. With short 
induction and a low dose of gas for inhalation, hypothermia and cardiorespiratory 
depression could be minimized. We sought to perform a standardized procedure for sedation 
and echocardiographic recordings to minimize variation in depth and length of the sedation. 
During pilot studies, we observed significant LV dilatation, decreased contractions and 
bradycardia with higher gas concentrations and/or prolonged sedation, especially in the 
presence of large MIs. The cardiodepressive effect is reflected in heart rate. The relatively 
high heart rates registered during our echocadiographic recordings, and the similar heart 
rates at the initial and the final examination, correspond well with a standardized procedure 
with low gas concentrations. 
 
Infarct size  
Estimation of infarct size in tissue post-mortem can be performed with a number of 
enzymatic and immunohistochemical stainings. In the early phase after coronary occlusion, 
it is difficult to distinguish reversible from irreversible damage. In contemporary 
experimental models, the triphenyl tetrazolium chloride (TTC) method is frequently used. 
TTC stains viable tissue red by a dehydrogenase dependent reaction, while the infarct zone 
is dehydrogenase deficient and remains unstained.94 It can be used early, ideally after 3 
hours of reperfusion to allow washout of dehydrogenase from the infarct zone, and is 
usually applied on 2 mm slices of fresh tissue after a freeze- thaw cycle. In acute models, 
scar formation and remodeling reduce the relative infarct size from 3 days and further, 
reducing the accuracy of TTC.  
When a collagenized scar has developed (after 2-3 weeks), histological staining for 
collagenized scar tissue, like Sirius red or trichrome staining, is frequently used. Indeed, 
Masson trichrome stained tissue sections have served as a gold standard for infarct size.95 
As the scar tissue will contract over time, this method will report a smaller infarct size, both 
absolute and relative, as compared to TTC staining or other measurements performed early.  
 52 
In our study, we did not use a reperfusion model, and hearts were harvested 4 weeks after 
the AMI. Furthermore, we were interested not only in infarct size, but also cell engraftment, 
differentiation, morphology and vascularization. The relative infarct size in comparison 
between groups was of interest, and similar time had elapsed since the AMI in all groups. 
Thus, collagen staining was appropriate to meet our needs, and staff with experience in 
Masson Goldener staining was available in the Department of Pathology. 
The method for quantitative measurement of infarct size was based on the following 
considerations: 
First, since animals had variable weight due to the use of both genders, some variation in 
age and variable presence of oedemas and cardiac cachexia, a relative measure for infarct 
size should be used, i.e scar tissue as a fraction of heart tissue. As paraffine embedded tissue 
was available, and tissue sections were also needed for cell tracking and other analyses, scar 
tissue throughout the heart would best be evaluated by the use of full volume stack of serial 
short axis tissue sections. The amount of infarct or scar on each slide can be quantified in 
several ways. Infarct zone has been measured as sector of a 360 degree circumference. 
Others have used graphic software to delineate infarcted areas. However the presence of 
variable transmurality, scattering, and islets of regenerative cells limit the applicability of 
the sector method, and the delineation method may also be difficult to apply if there are 
cracks in the tissue on the slide, scattering of fibrotic tissue, or islets of regenerated or 
spared myocardium. Software providing the correct size of traced areas on microscopy 
derived images is important for reliability. In small animals with thin walls even in the left 
ventricle, a subendocardial rim of myocardium is often spared after coronary occlusion, 
resulting in high variation in transmurality. As cell therapy is expected to be most effective 
in the border zone, infarct size should be measured in all dimensions. Based on these 
considerations, we decided to quantify scar tissue by the tissue morphometry approach as 
described. The size of the grid was determined after a pilot study to ensure adequate 
numbers of “hits” pr. slide. In the pilot study, we also evaluated infarct size in the groups to 
estimate the sample size. The grid was superimposed by the computer in a random direction, 
to exclude bias by a specific orientation of the images. Typically, 600-800 hits or non-hits 
were counted pr. slide. This method provides high spatial accuracy to overcome the 
limitations of other approaches, and a similar approach as been applied by others.96 The 
main limitation of pointcounting is the workload, but to some degree high methodologic 
accuracy will allow reduction in sample size.  
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Cell tracking 
If beneficial functional or structural effects after cell therapy are observed, it is of great 
mechanistical interest to clarify the presence of engraftment of transplanted cells in the 
recipient.  In order to identify even low numbers of engrafted cells, the method should be 
sensitive. It also had to be applicable in formalin fixed, paraffine embedded tissue, and it 
had to allow further staining procedures on the same slide for clarification of cell phenotype. 
In our view, high specificity was also of utmost importance, as transdifferentiation events 
should not be overreported. 
MSCs are not distinguished from other cell lines by a specific phenotypic marker, but rather 
from characteristics in culture (plastic adherence and multilineage differentiation). MSCs 
are also present in the recipient animals. Thus the donor cells had to be identified either by 
staining all cells with a fluorescent marker before transplantation or by identification of 
donor-derived cells in situ with another specific marker- for instance a marker specific for 
human cells. Other studies have used transgenic cells expressing fluorescent proteins like 
green fluorescent protein (GFP). GFP may affect functionality of donor derived cells97, 98. 
Functional adverse effects of other transgenic proteins have been even less investigated. 
Fluorescent substances like Dil or PKH 56 dissolves in the cell membranes of donor cells 
and provide reliable fluorescent signals before transplantation. However, evidence suggest 
retention of only a small percentage of cells at the site of injection.52 The proportion of cells 
washed out vs. the proportion of cells dying in situ, either by ischemia, apoptosis or 
destruction due to non-specific or specific immune responses has not been clarified, and 
soluble fluorescent markers may cause background signals from membrane fragments 
without relation to viable cells after cell destruction in situ. In case of cell proliferation, we 
would also expect attenuation of fluorescence from a dissolved marker in the mother cell 
membrane.  
After transplantation, human donor cells can be distinguished from murine recipient cells 
either by immunostaining against human specific epitopes (proteins) or by in situ 
hybridization to human specific DNA (or RNA) sequences. Antibodies specific for human 
HLA-ABC have been used, but the assay has only been successful in frozen sections. FISH 
have been used for cell tracking either by using a FITC- conjugated probe against the human 
specific ALU- sequence99 or by using probes specific for the X and/or Y- chromosome.100 
The signals from the X and Y chromosomes are very small, appearing as a small spot within 
the nucleus. The size of the signal could affect sensitivity and feasibility during screening 
for transplanted cells. Also, information about gender of our donors was not available. To 
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allow co-staining for markers of cell phenotype, it was appropriate to use only one 
bandwidth for cell tracking. Based on these considerations, we decided to use the Alu probe. 
Pilot studies were performed to ensure that the FISH procedure did not interfere with the 
result and specificity of the subsequent immunostaining, and that immunostaining did not 
attenuate the FITC- signal. During these studies, we did not identify background 
fluorescence in the cell nuclei that could lead to misinterpretation of the FITC signals. There 
was moderate autofluorescence from cross-striated muscle like the myocardium, but this 
appeared mainly in the red spectrum and was confined to the cytoplasm. RBCs and 
eosinophilic WBCs were also autofluorescent, but these signals were easily identified by 
size (RBCs are small), localization (RBCs were mainly clustered within blood vessels), 
morphology (RBCs were not nucleated, eosinophils had bilobed nuclei) and the bandwith of 
the signal (autofluorescence is oftenly not specific to one band).   
 
Staining for phenotypic markers 
The antibodies for staining to clarify differentiation of the injected cells were selected 
according to the following priorities: 
 They had to perform with an acceptable signal to noise ratio in formalin fixed 
paraffin embedded tissue slides without interfering with the FISH signal. 
 If available, human specific antibodies were used, to ensure signals specific for 
donor derived cells.  
 Minimal background fluorescence. 
 Availability and former experience with the antibody in our department. A selection 
of antibodies to cover the most relevant cell types expected to be involved in 
myocardial regeneration was pursued.  
 
Troponin I is a structural protein located in the cytoplasm of mature cardiomyocytes. It is 
highly specific for cardiac tissue. 
Nkx 2,5 is a protein appearing in immature cardiomyocytes/ cardiac precursor cells. It was 
used mainly to ensure that we did not overlook transdifferentiated cells too immature to 
express troponin. 
Desmin is a structural protein involved in the cell-cell binding and interaction (the 
intercalated disk). Its presence in donor derived cells would indicate the formation of gap 
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junctions- a prerequisite for rapid intercellular conduction of action potentials during cardiac 
depolarization. 
	
	 is a structural protein specific for smooth muscle, typically 
found in the walls of small and medium sized arteries. 
CD 31 is a marker specific for endothelial cells. 
Red fluorescence conjugated secondary antibodies, and for anti-troponin I, biotinylated 
secondary antibody with a red fluorescence conjugated streptavidin tertiary antibody, were 
selected. 
All antibodies were tested for sensitivity and specificity in human hearts and rat hearts with 
positive and negative control stainings. After FISH and the subsequent co-stainings, slides 
were mounted with Vectashield with DAPI. The final staining protocols performed well to 
obtain sections with blue fluorescent nuclei (DAPI), green fluorescent FITC signals in 
nuclei in human cells, and red fluorescent signal from the differentiation-staining.  
 
Vascular density 
For evaluation of vascular density, we performed enzyme- linked immunostaining against 
blood vessels in rats. Only few antibodies perform well in paraffine embedded rat heart 
tissue. Despite some background staining in the myocardium, we selected the VE- cadherine 
antibody after extensive testing and titration. VE- cadherin (Cadherin-5) is an endothelial 
specific molecule localized in the adhesion between endothelial cells.101 The analyses for 
vascular density required a high number of slides, and visualization of tissue morphology 
was important. Therefore, light microscopy was preferable. Diaminobenzidine (DAB)/ 
peroxidase was used as the chromogene assay, and haematoxylin was used as 
counterstaining for better morphology. Vascular density can be evaluated in several ways, 
and there is no generally accepted standard for analysis. Most publications describe either 
the number or the area of vessels stained with a given marker within a “representative” area 
of tissue.  After reviewing the litterature and performing microscopy of some tissue slides, it 
was apparent that the size of blood vessels was highly variable, the vascular density- 
measured either by number or by area- was very different in different tissues (myocardium, 
scar, other stromal/ connective tissue) and the composition of tissue was different on 
different sections, depending on the presence and the size of an infarct zone and a border 
zone. Based on these considerations, we decided to vascular densities separately and 
specific for scar tissue, borderzone connective tissue, and the intact myocardium. The field 
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selected for quantification was determined by a prespecified pattern for localization, as 
illustrated in figure 11. 
Figure 11.   
 
 
Illustration of the prespecified pattern for selection of microscopy-fields for determination of vascular density. 
The circles, representing the fields, are superimposed on a Masson- Goldener stained tissue section. Black 
circles= scar tissue. Red circles= borderzone. Yellow circles= remote myocardium. 12.5x magnification   
 
 
On each section, we counted two separate fields from the scar tissue. We aimed for two 
fields with high transmurality as far apart as possible. High transmurality had priority to 
obtain adequate numbers of hits. Two fields from the borderzone- one field from each end 
of the infarct sector. Two fields from intact myocardium, well separated, but not in 
conjunction with the infarct zone. Fields with high numbers of cross-sectioned vessels were 
preferred. We decided to measure the vessels by area. A simple count of the number of 
vessels in each field would not reflect the dimensions of the vessels. The vessel area should 
also be indexed with respect to the area of tissue evaluated. The majority of observed 
vessels in the scar tissue and in the remote myocardium had diamet#?
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assumed it was unlikely that the main beneficial effect of cell therapy would be de novo 
generation of large blood vessels in these tissues. We therefore excluded vessels with 
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, to avioid large random variability in 
vessel count. A relative area covered by vessel lumina or walls, corrected for the area of 
tissue evaluated, was then obtained by tissue morphometry with pointcounting on a grid as 
described for infarct size. With our method, the registered vascular density was low in scar 
tissue, higher in preserved myocardium and much higher in the borderzone tissue. This 
finding is well in accordance with the low metabolic demands in scar tissue (resulting from 
an ischemic injury), and with our definintion of borderzone tissue, which mainly comprised 
eventual granulation tissue localized between scar tissue and intact myocardium. 
Granulation tissue is defined by its “granulated” appearance due to high density of small 
blood vessels. As large vessels, by definition, were not excluded from the vessel count in 
the borderzone tissue, the definition clearly contributed to the relatively high vascular 
density counted in our study. However, counting was performed with the same criteria on 
all sections, and the observer was blinded to treatment allocation by recoding the images, 
thus, no bias was introduced in the comparison between groups.  
Vascular density was higher in scar tissue in the MSC groups than in the control group, but 
not significantly different between groups in the other tissues. However, the amount of 
granulation tissue in the borderzone area was higher in the MSC groups. Thus, we can 
hypothesize that counting of “random” fields from the sections probably would have 
retrieved higher vascular density overall in MSC treated hearts, in accordance with other 
studies. This distribution of increased vascular densities makes sense, as an increase of 
vascular density in intact myocardium should not be expected (there is no physiologic 
demand), nor lead to improved LV function. The scar tissue may have been generated under 
the influence of eventual angiogenic paracrine factors, but do not contribute to contractility. 
An improvement of LV function after cell therapy in AMI should mainly result from the 
salvage or regeneration of cardiomyocytes. We found an enlarged active borderzone 
suggesting ongoing reparative processes in a well vascularized environment, with higher 
probability of reconstitution of contractility than in an establisched scar tissue. However 
further identification of the mechanisms behind reduced scar formation and improved LV 
function was not addressed in our study. 
The morphometric approach is well recognized also in quantitative tissue analysis and 
evaluation of vascularization76, and the major limitation is the workload. Publications with 
direct comparison of methods for quantification of vascular density in experimental cardiac 
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animal studies have, to my knowledge, not been published. We analyzed 6 random sections 
pr. animal. The number of sections pr. animal was determined by pilot calculations to obtain 
representative average values for all animals.           
 
Our results in comparison to other studies 
As a general comment, different groups use different strains of animals, have different cell 
clones and use different methods, all factors making a direct quantitative comparison of 
results difficult to interpret. Our study can be compared with the study by Mazo et al.96 
They compared intramyocardial injections of ADSCs, adipose derived cardiomyogenic cells 
and mBMCs with placebo. The cells were harvested from GFP+ transgenic mice and 
injected in rats 1 month after ligation of LAD. Rats were immunosuppressed with 
cyclosporin A and harvested 1 week and 1 month after injections. GFP positive cells were 
found in the hearts after 1 week, but not 1 month. Except from the cardiomyogenic cells 
already expressing troponin at the time of injection, no signs of (trans-) differentiation 
towards myocardial-, endothelial or smooth muscle lineages occured. Despite this absence 
of long term engraftment, they observed, for ADSCs vs. placebo, improved LVEF by 
echocardiography (appx. from 28 to 45 % in the ADSC group vs 30 to 32 % in placebo 
group), reduced infarct size (11% in the ADSC group vs 20% in placebo group), improved 
vascular density (appx 50 % more lectin positive vessels pr mm3 in the ADSC group vs the 
placebo group). 
LVEF at baseline was similar with our study. There was an insignificant trend for increase 
of LVEF in the control group, compared to unhanged LVEF in the control group in our 
study. In the ADSC group, they found about 15 % increase in LVEF, as compared to 6 % in 
the SM-MSC group and 4 % in the ADSC group in our study. In Mazo’s study, infarct size 
was 20 % in the placebo group and 11 % in the ADSC group. In our study, infarct size was 
26 % in the placebo group and 16 % in both groups receiving MSCs. Thus, cell treated 
animals had a larger relative effect on infarct size and smaller infarcts at the end of Mazos 
study. The change in infarct size corresponds well both between studies and with the results 
by echocardiography. Mazo et. al observed significant increase in vascular density, 
performing separate stainings for lectin and SMA positive vessels, but only in the infarct 
zone. The treatment effect on both infarct size, LVEF, and vascular density seem smaller in 
our study than in Mazos study. This may be explained by less efficient cells or less accurate 
cell injections, but may also reflect differences in timing of the injections, the animals used 
or effects of concomitant immunosuppression.  
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In Mazo’s study cells were not retrieved after 4 weeks, and this is in accordance with a few 
other studies where cells are not identified some time after transplantation. After 1 week, 
there was no indication that cells were expressing markers suggesting transdifferentiation. 
In our study, small clusters of cells were found in the infarct zone after 4 weeks, but we did 
not identify markers from other lineages. This in contrast to several studies reporting long 
term engraftment of cells and differentiation of MSCs to endothelial cells, smooth muscle 
cells or even cardiomyocytes.  
Cell engraftment depend on a number of factors including cell type, dose, mode of 
administration, timing after an ischemic event, cell preparation, time elapsed from injection 
till counting, and also the method for counting (radionuclide markers, MRI, 
bioluminescence, histological methods), eventual thickness of tissue sections, use of 
traditional light microscopy vs confocal microscopy and also the sensitivity and specificity 
of the cell marker used will influence the final number reported.   
Regarding differentiation studies, cells with different baseline characteristics have been 
used. Some of the observations have been made in vitro, cells have been cultured with or 
without use of growth factors, and some cells have been modified by demethylating agents 
like 5-azacytidine. Some have injected cells in healthy myocardium, which provide a very 
different extracellular environment as compared to the infarct zone or the borderzone. It 
should also be emphasized that expression of single surface markers not necessarily indicate 
a functional phenotype, and correct interpretation of the microgram and correct specificity 
of the antibody must be assumed. Autofluorescence and cell fusion are also methodological 
issues that have been discussed.20-22, 102  
Our findings of small numbers of engrafted cells, without a significant proportion of cells 
transdifferentiating during 4 weeks of observation, and a moderate decrease in infarct size, 
improved LV function and increased vascular density, correspond well with a majority of 
other publication. To date, there is little evidence supporting that a majority of injected 
MSCs engraft and differentiate to endothelial cells, SM cells or cardiomyocytes. Cell 
therapy with MSCs improves LV function, but mechanisms other than cardiomyogenic 
differentiation of transplanted cells must be involved. 
 
Mechanisms involved in the regenerative process 
In theory, the main mechanisms involved in myocardial regeneration by cell therapy after 
AMI would be: 
 generation of cardiomyocytes from the injected cells  
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 generation of myocardium by mobilization, activation, stimulation and/or 
chemotaxis of resident or circulating progenitor cells 
 myocardial salvage by reduced apoptosis 
 improved vascularization, either by differentiation to vascular cells or by stimulation 
of recipient angiogenesis  
 reduced fibrosis 
 
Current evidence support that large numbers of bona fide cardiomyocytes in a cell therapy 
approach  can be produced from pluripotent stem cells, either as ESCs103-105 or eventually 
from iPS cells106, 107, but important ethical and methodological issues have to be resolved 
before human use of these cells can be implemented.108-110 Although generation of 
cardiomyocytes from other cell types, including MSCs, have been reported20, 46, these 
findings are controversial and, at best, very rare events.100  In our study, transplanted cells 
did not differentiate to express neither a cardiomyocyte phenotype nor markers of a smooth 
muscle or endothelial cell phenotype, and cells were not localized within healthy 
myocardium nor vessel walls. Nevertheless, MSCs reduced fibrosis or scar formation and 
improved vascularization without differentiation to vascular cells themselves. The observed 
improvement in LV function indirectly suggests myocardial salvage and/or generation of 
myocardium by resident or circulation progenitor cells. Thus, our study supports that several 
mechanisms are involved, but the study was not designed to identify more detailed 
mechanisms of action, i.e. identification of soluble factors mediating these effects. 
However, accumulating evidence support the observation of improved LV function after 
cell therapy in the absence of differentiation to de novo cardiomyocytes. The relative 
importance of the aforementioned mechanisms is not clear, and these effects may be 
mediated by one or several soluble factors. Protagonists of the paracrine hypothesis have 
proposed > 30 putative paracrine factors.111 Effects on the inflammatory response in 
ischemia and infarction may also be involved. Myocardial protection after MSC- injections 
may be mediated by IL-!&
	|}~-1, VEGF, TSG-6, adrenomedullin, 
EPO and FGF-2, of which many influence the Akt pathway.51, 111, 112 Angiogenesis may be 
mediated by TSG-6, VEGF, nitric oxide, angiopoietin, bFGF, PDGF and MCP-1, all factors 
shown to be upregulated or released after MSC injections113-115 Attenuated fibrosis after 
cardiac MSC therapy has been observed in several studies50, 116-119, with reduced 
proliferation of fibroblasts119 and reduced formation of collagen I and III. Reduced levels of 
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TIMP 1 and TGF-|
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 118   MSCs produce TSG-6, shown to 
inhibit apoptosis and induce angiogenesis.51 MSCs also, especially when exposed to 
hypoxic conditions113, secrete IGF-1, HGF and SDF-1120, that may attract and stimulate 
endogenous (cardiac) progentitor cells.121  Regenerative effects have been demonstrated 
after injection of merely the supernatant of cultured MSCs, confirming that soluble factors 
are involved.122  On the other hand, regenerative effects have been shown to improve 
significantly if cell survival is enhanced by overexpression of the pro-survival Akt- gene, 
suggesting that the persisting presence of transplanted cells is important.123   
Experimental studies have suggested that MSCs have the characteristics needed to 
regenerate myocardium by all the mechanisms mentioned. However, transdifferentiation of 
MSCs to express cardiomyocyte markers have only been observed in a few studies, and 
small numbers of myocytes generated cannot the significant improvement in LVEF. Thus, 
the process of transdifferentiation need to be better characterized and enhanced to be 
clinically applicable. The most important paracrine factors must be identified, and for each 
of the factors, the ideal dosing and spatial and temporal distribution need to be clarified.  
 
Clinical MSC studies 
The clinical experience with cardiac MSC therapy is not as extensive as with unfractioned 
mBMCs, partly because mBMCs had been used in bone marrow transplantations for almost 
40 years before the MSCs were coined. In 2004 Chen et al reported a randomized controlled 
study from China.124 69 patients with AMI were randomized to receive intracoronary 
injections of none marrow derived MSCs or placebo 18 days after the acute event. 48 to 60 
x 109 cells were injected by stop-flow technique. After 3 months most parameters LV 
function and remodeling were significantly better in the MSC group. In another phase I 
cohort study published in 2005, Katritsis et al cultured bone marrow derived MSCs from 
patients with anteroseptal ST-elevation MI.125 2-4 x 106 cells were injected 8 to 1560 days 
after AMI. After 4 months, significant improvement in WMSI and viable segments during 
dobutamine-echocardiography was observed. In a phase I cohort study on 10 patients with 
previous coronary artery bypass grafting (CABG) and stable no-option angina, 7.5 x 106 
mBMCs mixed with 7.5 x 106 MSCs were injected intracoronarily.126 No adverse events 
were reported, and after 6 months LVEF, ischemia and quality of life was improved. In 
another Chinese study, patients received intracoronary MSC injections after recanalization 
and stenting of a chronically occluded LAD. Significant improvement in LVEF and exercise 
capacity was observed in the MSC group (n=22), but not in the control group (n=23).127 
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The feasibility of intracoronary MSC- injections is controversial, as vascular plugging has 
been reported. Most ongoing studies use guided catheter systems for transendocardial 
delivery of cells. In a study by Friis et al, 31 patients with no-option angina were included to 
receive autologous bone marrow derived MSCs stimulated with vascular endothelium 
growth factor (VEGF).128 10-15 injections were performed to transplant a mean of 21.5 x 
106 cells. No procedural complications were observed, and after 6 months patients had 
increased exercise capacity, and reduction in CCS class, angina attacks and nitroglycerine 
consumption. 
The recently published C-CURE trial included patients with heart failure and NYHA class 
II-III.129 Bone marrow derived MSCs were treated with growth factors to stimulate 
cardiomyogenic differentiation of the MSCs. This cocktail had previously been tested in an 
animal model.130  In the clinical double blind study (n=45), catheter based injections of 
cardiopoietic MSCs provided significant improvement in LVEF (5.2±0.6% vs 1.0±0.7%, 
p<0.01) and 6 min walking distance (+52±19 m vs -21±14 m, p<0.01) as compared to the 
control group. Intravenous administration of allogeneic MSCs has also been attempted in 
one randomized double blind study with 53 included patients.49 High dose and low dose of 
the commercial cell product Provacel® was compared to placebo by infusion 1-10 days after 
reperfused AMI. The primary safety endpoint was met, and provisional efficacy endpoints 
showed lower occurence of ventricular arrhythmias and a trend for better LV function in the 
MSC groups. 
Thus, most clinical studies report beneficial effects of MSC therapy. However, a variety of 
modes of administration, cell doses, timing after AMI, subsets of cells and endpoints have 
been used. Most of the studies are not randomized or double blinded. The number of 
patients is limited, and no study has been powered to evaluated effects on clinical endpoints. 
As MSCs are not characterized by a specific phenotypic marker, the cell populations are 
probably heterogeneous and standardized protocols for cell preparation are warranted. 
 
Lost in translation 
For the cell types investigated in both experimental and human studies, ie skeletal 
myoblasts, mBMCs and MSCs, there is a gap between the substantial regenerative effects 
reported in some experimental studies and the very modest effects observed in clinical 
studies. There are several plausible factors explaining observation: 
 Dose. Myocardium contains approximately 20 x 106 cardiomyocytes per gram of 
tissue. In our experimental study, the AMI affected 20-30 % of a 0.5-1 g left 
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ventricle, i.e. < 5 x 106 cells were lost. 3 x 106 MSCs were injected. In a large human 
AMI, 20-30 % of a 300-350 g ventricle is lost, i.e 1-1.5 x 109 cardiomyocytes.1, 131, 
132 In the REPAIR-AMI study, 236 x 106 mBMCs were injected, of which 1.5 % 
were CD 34 positive, thus containing the fraction of cells with stem cell properties. > 
90 % of injected cells are lost within hours.40 Thus, less than 400.000 stem cells are 
expected to regenerate 1-1.5 x 109 cardiomyocytes. 
 Size. Cells are injected to engraft in ischemic or infarcted tissue. The vascular supply 
is impaired. The volume of the infarct zone is 300 times larger in humans than in rats 
The murine left ventricle has a wall thickness of about 1 mm, in comparison to the 
human heart with an end-diastolic LV wall thickness normally within the range 7-11 
mm. Based on simple geometric assumptions, adequate layers of transplanted cells 
have to be at least 10-fold thicker in humans than in rats. The same maximum 
distance for passive diffusion of oxygen and nutritients to cells will apply in the two 
species, suggesting that the likelihood for survival of an adequate number of cells 
after simple injection will decrease with the size of the subject. 
 Properties of the cell product. It has been documented that migratory and 
proliferative properties of progenitor cells are progressively impared depending of 
the occurence of cardiovascular risk factors like age, diabetes and smoking. Thus, 
autologous cells harvested from patients in the population suffering from 
postinfarction heart failure do not have the same regenerative potential as progenitor 
cells from young and healthy individuals (animals or humans).133  
 Interspecies variations. Several differences in physiology between species are 
known.134 Mice have a metabolic rate (pr. weight) 3 times higher than men. Cancer 
risk in laboratory mice is substantially higher than in man, suggesting genetic 
instability. In the newt, spontaneous regeneration of heart and limbs occur after 
injury. Although the capacity for spontaneous myocardial regeneration in mice seem 
to be lost within 1 week after birth135, interspecies differences in regenerative 
processes are not fully explored.   
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Conclusions 
 
In patients from the ASTAMI study, mBMC therapy did not significantly influence clinical 
events, left ventricular function, infarct size, exercise capacity or quality of life during 3 
years follow up. The conclusion is limited by the moderate number of patients included in 
the study. However, the result is supported by accumulating evidence from other trials 
suggesting, at best, moderate improvement in LVEF after mBMC injections in AMI. The 
effect of mBMC therapy on patient survival has not yet been addressed in an adequately 
designed clinical randomized trial, and the optimal cell dose, timing, method for 
administration and mechanisms of action are not clarified.  
 
Human derived MSCs from skeletal muscle (SM-MSCs) and adipose tissue (ADSCs) 
improve LV function when injected intramyocardially in nude rats 1 week after after 
permanent ligation of LAD. The improvement in LV function is related to an observed 
reduction in infarct size, increase in granulation tissue in the borderzone, and increase 
vascular density observed in animals receiving MSC injections. Small clusters of MSCs are 
observed in the scar tissue and borderzone after 4 weeks. No transdifferentiation to 
cardiomyocytes, endothelial cells or smooth muscle is observed, suggesting that that the 
MSCs contribute to LV regeneration by other mechanisms, like stimulation of blood vessel 
formation and modulation of scar formation. 
 
 
 
 
 
Limitations 
 
Detailed methodology in cardiac MRI, quality-of-life analyses, cell harvesting and -
processing are not part of the present thesis. In the overview of experimental and clinical 
cell therapy in heart disease, studies using bone marrow cells and mesenchymal stem cells 
after acute myocardial infarction are emphasized. 
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Future perspectives 
At present, the evidence does not justify implementation of cardiac cell therapy in routine 
clinical practice. True regeneration of cardiac tissue to restore cardiac systolic function will 
require further progress in research. The technique of induced pluripotency in autologous 
cells (iPS-cells)136 may circumvent the ethical and immunological issues hampering the use 
of ESCs. However, iPS cells can be genetically and epigenetically heterogeneous, and there 
will be a tug of war between pluripotency and potential for proliferation versus lineage 
commitment and differentiation control.137-139 Non-genomic reprogramming and further 
insight in the signaling pathways of differentiation will increase efficacy and safety.140 
Tissue engineering with patches containing vascular- and myogenic cells in a scaffold of 
biomaterials may promote engraftment and survival of sufficient numbers of contractile 
cells.141-143 However, a single cell type and and one single application will not cover all 
potential indications for cardiac cell therapy. In acute settings, in vitro culture of cells and 
iPS- based tissue engineering will be too time consuming, and in no-option angina, 
angiogenesis to support already existing cardiomyocytes is preferable. In these applications, 
adult stem cells may still serve as the best available agents, but there will be a search for 
adult cell types with higher regenerative and/or angiogenic potential to replace the use of 
unfractioned mBMCs. The paracrine mechanisms will hopefully be defined, and 
recombinant factors may replace cell therapy in some applications. Clearly, there is a 
clinical demand for efficient cardiac regeneration, and cell therapy has a great potential, 
conceptually. Convincing results from properly designed and conducted clinical trials will, 
however, be pivotal for future clinical use.  
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Errata:
Forprinting,anewpage2wasadded,andfurtherpagenumberschangedaccordingly
Page7line11;”leftventricular”hasbeenadded
Page10line25;“twostem”hasbeenchangedto“twostem”
Page11line14;“has”hasbeenchangedto“have”
Page13line34;“injection”hasbeenchangedto“injections”
Page27line2;“3shortaxiscineloops”hasbeenchangedto“2short…”
Page27line47;figure1,2and3havebeenchangedtofigure2,3aand3b,andreferencestofigure
numbers(onpage27and28)havebeencorrectedaccordingly.
Page38line30;“whennew”hasbeenchangedto“whenanew”
Page40line2;“demonstrate”hasbeenchangedto“demonstrates”
Page42line28;“(REF)”hasbeenremoved
Page43line14;“in”hasbeenadded
Page47line7;one“.”Hasbeenremoved.
Page72line39;reference120hasbeenupdated.
